Ad hoc announcement pursuant to Art. 53 LR A conference call will be held today at 14:30 CEST, 13:30 BST, 08:30 EDT. Details are at the end of this statement. Revenue from contracts with customers
Santhera and ReveraGen to Present New Data with Vamorolone at 2022 Parent Project Muscular Dystrophy Conference Pratteln, Switzerland, and Rockville, MD, USA, June 9, 2022 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce presentations of new data with vamorolone in Duchenne mus.
Pratteln, Switzerland, and Rockville, MD, USA, June 9, 2022 - Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce presentations of new data with vamorolone in Duchenne muscular
Pratteln, Switzerland, December 6, 2021 - Santhera Pharmaceuticals (SIX: SANN) is pleased to invite investors, shareholders, media representatives and interested parties to join a conference call